Type 1 Diabetes Clinical Trial
Official title:
Sensor-Augmented Continuous Correction in Insulin Pump-Treated Type 1 Diabetes
The potential of currently available diabetes technologies could be further exploited. The
investigators propose that sensor-augmented insulin pump therapy may be improved by
continuous correction, i.e. continuous evaluation of the need for correction boluses. In
practice, this is carried out by running the bolus calculator every 10 minutes. The glucose
sensor will provide the bolus calculator with glucose input. Many times, the bolus
calculator will come to the result that no insulin is needed. However, when the blood
glucose is above the pre-set target value and a correction bolus is needed, an appropriate
bolus is automatically delivered by the insulin pump.
The investigators hypothesize that sensor-augmented continuous correction insulin pump
therapy can reduce hyperglycemia without increasing the risk of hypoglycemia in patients
with type 1 diabetes.
Status | Terminated |
Enrollment | 2 |
Est. completion date | December 2014 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age = 18 years - T1D = 3 years - CSII = 1 year - HbA1c = 8.0% (64 mmol/mol) Exclusion Criteria: - Pregnancy or nursing - Hypoglycemia unawareness - Gastroparesis - Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during or within 30 days prior to the study - Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Denmark | Hvidovre University Hospital | Hvidovre |
Lead Sponsor | Collaborator |
---|---|
Hvidovre University Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Mean absolute relative difference. | CGM accuracy will be evaluated with Hemocue glucose values as reference (mean absolute relative difference). | Every 5 min for 9 hours on each study day. | No |
Primary | Percentage of time CGM values are in the target range 3.9-8.0 mmol/l in the time period 8:00-17:00. | The primary outcome is difference in the percentage of time CGM values are in the target range 3.9-8.0 mmol/l in the time period 8:00-17:00 on CC-days and Control-days. | Every 5 min for 9 hours on each study day. | No |
Secondary | Mean CGM glucose value. | Every 5 min for 9 hours on each study day. | No | |
Secondary | Percentage of time when CGM values are < 3.9 mmol/l. | Every 5 min for 9 hours on each study day. | Yes | |
Secondary | Percentage of time when CGM values are > 8.0 mmol/l. | Every 5 min for 9 hours on each study day. | No | |
Secondary | CGM standard deviation. | Every 5 min for 9 hours on each study day. | No | |
Secondary | Number of hypoglycemic episodes. | Every 5 min for 9 hours on each study day. | Yes | |
Secondary | Amount of insulin delivered. | Every 30 min for 9 hours on each study day. | No | |
Secondary | Positive Incremental Area Under the Curve | Every 5 min for 9 hours on each study day. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A | |
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|